title: Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.
abstract: OBJECTIVE
  Studies have shown the bactericidal potential of econazole and clotrimazole against Mycobacterium tuberculosis under in vitro and ex vivo conditions along with their synergism with conventional antituberculosis drugs. These molecules were also found to be effective against different multidrug resistant (MDR) M. tuberculosis isolates in vitro. Hence the present study was designed to evaluate the in vivo antimycobacterial potential of moxifloxacin and econazole alone and in combination against multidrug resistant tuberculosis (MDR-TB) in a mice model.
  
  
  METHODS
  Mice were infected with 2.5×10 [7] bacilli of MDR strain of M. tuberculosis by aerosol route of infection. After four weeks of infection, chemotherapy was started orally by moxifloxacin 8.0 mg/kg body wt and econazole 3.3 mg/kg alone and in combination, as well as with four first line anti-tuberculosis drugs as a positive control. The animals were sacrificed and the lungs and spleen were excised under aspetic conditions. The tissues were homogenized with sterile normal saline, an aliquot of the homogenate was plated on Middlebrook 7H11 agar supplemented with oleate albumin dextrose catalase (OADC) and incubated at 37°C for four weeks. The number of visible and individual colonies were counted.
  
  
  RESULTS
  The first line anti-tuberculosis drugs (RIF+INH+EMB+PZA) after eight weeks of therapy had no impact as the bacillary load in lungs and spleens remained unchanged. However, econazole, moxifloxacin alone as well as in combination significantly reduced the bacillary load in lungs as well as in spleens of MDR-TB bacilli infected mice.
  
  
  CONCLUSIONS
  Co-administration of the two drugs (econazole and moxifloxacin) to MDR-TB strain JAL-7782 infected mice exhibited additive effect, the efficacy of the drugs in combination being higher as compared with ECZ or MOX alone. These results were substantiated by histopathological studies. This study suggests the utility of econazole for the treatment of MDR tuberculosis and warrants further work in this direction.
authors.affiliation: Experimental Animal Facility, National JALMA Institute for Leprosy & Other Mycobacterial Diseases (ICMR), Agra, India.
authors.forename: U D
authors.initials: UD
authors.lastname: Gupta
authors.forename: N
authors.initials: N
authors.lastname: Vemuri
authors.forename: P
authors.initials: P
authors.lastname: Gupta
authors.forename: V
authors.initials: V
authors.lastname: Kumar
authors.forename: P
authors.initials: P
authors.lastname: Tanushree
authors.forename: G K
authors.initials: GK
authors.lastname: Khuller
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004464:Econazole / Q000008:administration & dosage; D024841:Fluoroquinolones / Q000008:administration & dosage; D006801:Humans; D051379:Mice; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
chemical_list: D024841:Fluoroquinolones; D004464:Econazole; D000077266:Moxifloxacin